OTCMKTS:PFSCF - ProMetic Life Sciences Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.3820 -0.01 (-2.55 %)
(As of 10/21/2018 03:44 PM ET)
Previous Close$0.3820
Today's Range$0.3820 - $0.4020
52-Week Range$0.3336 - $1.4699
Volume37,097 shs
Average Volume43,160 shs
Market Capitalization$274.32 million
P/E RatioN/A
Dividend YieldN/A
Beta4.07
ProMetic Life Sciences Inc., a biopharmaceutical company, develops bioseparations, plasma-derived therapeutics, and small-molecule therapeutic products. It operates through three segments: Small-Molecule Therapeutics, Plasma-Derived Therapeutics, and Bioseparation Technologies. The company offers its technology platform for purification of biologics, drug development, proteomics, and elimination of pathogens; and develops small molecule therapeutic products targeting unmet medical needs in the fields of fibrosis, inflammation, autoimmune diseases, oncology, and nephropathies. The Small-Molecule Therapeutics segment's lead product candidate is PBI-4050, which targets unmet medical needs, such as the treatment of idiopathic pulmonary fibrosis, chronic kidney diseases/diabetic kidney diseases, and metabolic syndrome and its resulting type 2 diabetes, cystic fibrosis related diabetes and liver steatosis, and Alström syndrome. The Plasma-Derived Therapeutics segment provides Plasma Protein Purification System, a multi-product sequential purification process for the extraction and purification of therapeutic proteins from human plasma. The Bioseparation Technologies segment develops and commercializes affinity chromatography products related to the bioseparation, pathogen reduction, and protein purification. The company was formerly known as Innovon Life Sciences Holdings Limited and changed its name to ProMetic Life Sciences Inc. in May 1998. ProMetic Life Sciences Inc. was founded in 1992 and is headquartered in Laval, Canada.

Receive PFSCF News and Ratings via Email

Sign-up to receive the latest news and ratings for PFSCF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:PFSCF
CUSIPN/A
Phone1-450-781-0115

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$30.80 million
Price / Sales8.91
Cash FlowN/A
Price / CashN/A
Book Value$0.16 per share
Price / Book2.39

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-84,640,000.00
Net Margins-214.92%
Return on Equity-72.38%
Return on Assets-39.63%

Miscellaneous

Employees480
Outstanding Shares718,130,000
Market Cap$274.32 million

ProMetic Life Sciences (OTCMKTS:PFSCF) Frequently Asked Questions

What is ProMetic Life Sciences' stock symbol?

ProMetic Life Sciences trades on the OTCMKTS under the ticker symbol "PFSCF."

How were ProMetic Life Sciences' earnings last quarter?

ProMetic Life Sciences Inc. (OTCMKTS:PFSCF) posted its quarterly earnings results on Tuesday, August, 14th. The company reported ($0.04) earnings per share (EPS) for the quarter. The business earned $15.62 million during the quarter. ProMetic Life Sciences had a negative return on equity of 72.38% and a negative net margin of 214.92%. View ProMetic Life Sciences' Earnings History.

When is ProMetic Life Sciences' next earnings date?

ProMetic Life Sciences is scheduled to release their next quarterly earnings announcement on Monday, November 12th 2018. View Earnings Estimates for ProMetic Life Sciences.

What is the consensus analysts' recommendation for ProMetic Life Sciences?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProMetic Life Sciences in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ProMetic Life Sciences.

Who are some of ProMetic Life Sciences' key competitors?

Who are ProMetic Life Sciences' key executives?

ProMetic Life Sciences' management team includes the folowing people:
  • Mr. Pierre Laurin, Pres, CEO & Non-Independent Director (Age 57)
  • Mr. Bruce Pritchard, COO & Interim CFO
  • Mr. Patrick Sartore, Chief Legal Officer & Corp. Sec.
  • Mr. Bruce Wendel, Chief Bus. Devel. Officer (Age 64)
  • Dr. John Moran, Chief Medical Officer (Age 72)

How do I buy shares of ProMetic Life Sciences?

Shares of PFSCF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ProMetic Life Sciences' stock price today?

One share of PFSCF stock can currently be purchased for approximately $0.3820.

How big of a company is ProMetic Life Sciences?

ProMetic Life Sciences has a market capitalization of $274.32 million and generates $30.80 million in revenue each year. ProMetic Life Sciences employs 480 workers across the globe.

What is ProMetic Life Sciences' official website?

The official website for ProMetic Life Sciences is http://www.prometic.com.

How can I contact ProMetic Life Sciences?

ProMetic Life Sciences' mailing address is 440 Boulevard Armand-Frappier Suite 300, Laval A8, H7V 4B4. The company can be reached via phone at 1-450-781-0115 or via email at [email protected]


MarketBeat Community Rating for ProMetic Life Sciences (OTCMKTS PFSCF)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  63 (Vote Outperform)
Underperform Votes:  80 (Vote Underperform)
Total Votes:  143
MarketBeat's community ratings are surveys of what our community members think about ProMetic Life Sciences and other stocks. Vote "Outperform" if you believe PFSCF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PFSCF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/21/2018 by MarketBeat.com Staff

Featured Article: What are earnings reports?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel